Solu
3 known investors
Solu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Founders & leadership
PV
Phil VickersCEO / Leadership
MB
Michael BorettiLeadership
BT
Brandon TurunenLeadership
SS
Sergio SantillanaLeadership
EM
Enda MoranLeadership
KH
Kelly HonohanLeadership
MT
Marissa TimothyLeadership
JP
John PribisLeadership
Investors · 3
In the news
Frequently asked questions
- What does Solu do?
- Solu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
- Who are Solu's investors?
- Solu's investors include Astellas Venture Management LLC, Longwood Fund, Pappas Capital.